Tom Raggett,Editors, ,GATT and Patent Reform. The Global Strengthening of Patent Protection and the implications for the Pharmaceutical Industry (1996) FT Pharmaceuticals and Healthcare Publishing 1 85334 431 1 vii + 320.
- 作者David Hughes
- 卷第2卷
- 期第4期
- 印刷ISSN1359-6446
- 文件大小331.20KB
- 发表时间1997
- DOI10.1016/s1359-6446(97)89917-5
Lost in translation: CRF1 receptor antagonists and addiction treatmentShaham, Yavin; de Wit, Harriet · Neuropsychopharmacology · 2016
CRF1 receptor antagonists: treatment of stress-related disordersJohn H. Kehne; George D. Maynard · 2008
Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockoutKathleen Chu; George F. Koob; Maury Cole; Eric P. Zorrilla; Amanda J. Roberts · 2007
Antagonist effect of pseudohypericin at CRF1 receptorsUrs Simmen; Ionel Bobirnac; Christoph Ullmer; Hermann Lübbert; Karin Berger Büter; Willi Schaffner; Philippe Schoeffter · 2003
Development of CRF1Receptor Antagonists as Antidepressants and AnxiolyticsValdez, Glenn R · CNS Drugs · 2006
Can CRF1 receptor antagonists become antidepressant and/or anxiolytic agents?David H. Overstreet; Darin J. Knapp; George R. Breese · 2005
210. CRF1 receptor antagonists as novel putative antidepressants and anxiolyticsC.B. Nemeroff; M.J. Owens; K. Skelton; D. Guttman; J.T. Winslow; P.M. Plotsky · 2000